The Power of Probiotics to Combat Urinary Tract Infections: A Comprehensive Review

Abstract

Urinary tract infections (UTIs) are among the most common bacterial infections and can cause significant morbidity, particularly in women. Recurrent UTIs are a significant clinical problem, and current prophylactic measures, such as antibiotics, are associated with side effects and the risk of antimicrobial resistance. Probiotics, defined as live microorganisms that confer health benefits to the host, have emerged as a potential alternative to traditional treatments for recurrent UTIs. Probiotics can act by modulating the host's immune system, competitively excluding uropathogens, and producing antibacterial substances, such as bacteriocins. Clinical evidence supports the use of probiotics as a safe and effective intervention for the prevention and treatment of recurrent UTIs. However, selecting appropriate probiotic strains for UTIs can be challenging, and the safety and efficacy of probiotics depend on the strain, dosage, and timing of administration. The safety profile of probiotics is generally excellent, and side effects are usually mild and self-limiting. However, certain populations, such as immunocompromised and critically ill patients, may be at increased risk of adverse events, and caution should be exercised when considering probiotic use in these populations. Strategies for ensuring probiotic safety and efficacy include adherence to good manufacturing practices, rigorous testing for the presence of contaminants, and standardization of dosing and administration protocols. Despite the potential of probiotics for the prevention and treatment of recurrent UTIs, several challenges and limitations remain. These include limited access to high-quality probiotic products, challenges in selecting appropriate strains, and lack of consensus regarding optimal dosing and duration of probiotic use. Future research should focus on identifying optimal probiotic strains and regimens for the prevention and treatment of UTIs, understanding the role of gut microbiota in urogenital health, and developing new probiotic technologies and delivery methods.

Therapeutic effects of orally administration of viable and inactivated probiotic strains against murine urinary tract infection

“…The divergence in conclusions among studies may be attributed to the varying efficacy of probiotics, which heavily depends on the strain, dosage, and timing of administration. Currently, there is no consensus regarding the optimal dosing and duration of viable probiotic use for combating UTIs [ 40 ]. Notably, it may not be appropriate to directly compare the findings of our study with previous reports, as most of the existing literature focuses on viable probiotic supplementation for the prevention of recurrent UTIs, whereas our study primarily concentrates on the treatment of UTIs.…”

Isolation and Identification of Phenol-Degrading Bacteria from Iranian Soil and Leaf Samples

“…Various types of soil, water, and sediment samples have been investigated to identify phenol-degrading microorganisms, which can be applied to reduce phenol pollu-tion in the environment. In most cases, the results obtained in this research indicated that the C. testosteroni strain F4 bacteria isolated from the soil of pistachio orchards in Kerman, Iran, can be used to biodegrade phenol [27][28][29][30][31][32][33][34][35][36][37].…”